Korro Bio Hits the High Notes with $91.5M Series A | FierceBiotech
Korro Bio’s RNA-editing technology is based on research by MBL Senior Scientist Joshua Rosenthal. By Ben Adams Korro Bio has got off a meaty series A funding round, nabbing $91.5 million to run its platform of single-base RNA edits to treat a range of diseases. The Cambridge, Massachusetts-based biotech will use the cash haul toward